The global market for Biological Inactivated Vaccine was valued at US$ 892 million in the year 2024 and is projected to reach a revised size of US$ 1263 million by 2031, growing at a CAGR of 5.1% during the forecast period.

Biological Inactivated Vaccine Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Biological Inactivated Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Inactivated biological vaccines refer to a type of vaccine that uses physical or chemical methods (such as heat treatment, formaldehyde, β-propiolactone, etc.) to completely kill pathogenic microorganisms (such as viruses, bacteria, etc.), making them lose their infectivity and pathogenicity, while retaining their main antigenic structure to induce the body to produce a specific immune response. This type of vaccine is highly safe and suitable for people with weak immunity. It is widely used to prevent hepatitis A, polio, rabies, new coronavirus and other infectious diseases.

North American market for Biological Inactivated Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biological Inactivated Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Biological Inactivated Vaccine include Sanofi, GSK, Merck, Pfizer, SII, Valneva, Bharat Biotech, KM Biologics, Baxter, Bio Farma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biological Inactivated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Inactivated Vaccine.

The Biological Inactivated Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biological Inactivated Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, by Dosage Form and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biological Inactivated Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Dosage Form and by regions.

Scope of Biological Inactivated Vaccine Market Report

Report Metric	Details
Report Name	Biological Inactivated Vaccine Market
Accounted market size in year	US$ 892 million
Forecasted market size in 2031	US$ 1263 million
CAGR	5.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Inactivated Virus Vaccine Inactivated Bacterial Vaccine
Segment by Dosage Form	Liquid Vaccines Freeze-Dried Vaccines
Segment by Application	Humans Animals
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi, GSK, Merck, Pfizer, SII, Valneva, Bharat Biotech, KM Biologics, Baxter, Bio Farma, IVAC, Takeda, Emergent BioSolutions, Sinergium Biotech, China Biotechnology, Sinovac, Kangtai Biological, Zhifei Biological, AIM Vaccine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biological Inactivated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biological Inactivated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Biological Inactivated Vaccine Market growing?

Ans: The Biological Inactivated Vaccine Market witnessing a CAGR of 5.1% during the forecast period 2025-2031.

What is the Biological Inactivated Vaccine Market size in 2031?

Ans: The Biological Inactivated Vaccine Market size in 2031 will be US$ 1263 million.

Who are the main players in the Biological Inactivated Vaccine Market report?

Ans: The main players in the Biological Inactivated Vaccine Market are Sanofi, GSK, Merck, Pfizer, SII, Valneva, Bharat Biotech, KM Biologics, Baxter, Bio Farma, IVAC, Takeda, Emergent BioSolutions, Sinergium Biotech, China Biotechnology, Sinovac, Kangtai Biological, Zhifei Biological, AIM Vaccine

What are the Application segmentation covered in the Biological Inactivated Vaccine Market report?

Ans: The Applications covered in the Biological Inactivated Vaccine Market report are Humans, Animals

What are the Type segmentation covered in the Biological Inactivated Vaccine Market report?

Ans: The Types covered in the Biological Inactivated Vaccine Market report are Inactivated Virus Vaccine, Inactivated Bacterial Vaccine

1 Biological Inactivated Vaccine Market Overview

1.1 Product Definition

1.2 Biological Inactivated Vaccine by Type

1.2.1 Global Biological Inactivated Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Inactivated Virus Vaccine

1.2.3 Inactivated Bacterial Vaccine

1.3 Biological Inactivated Vaccine by Dosage Form

1.3.1 Global Biological Inactivated Vaccine Market Value Comparison by Dosage Form: 2024 VS 2031

1.3.2 Liquid Vaccines

1.3.3 Freeze-Dried Vaccines

1.4 Biological Inactivated Vaccine by Application

1.4.1 Global Biological Inactivated Vaccine Market Value by Application (2024 VS 2031)

1.4.2 Humans

1.4.3 Animals

1.5 Global Biological Inactivated Vaccine Market Size Estimates and Forecasts

1.5.1 Global Biological Inactivated Vaccine Revenue 2020-2031

1.5.2 Global Biological Inactivated Vaccine Sales 2020-2031

1.5.3 Global Biological Inactivated Vaccine Market Average Price (2020-2031)

1.6 Assumptions and Limitations

2 Biological Inactivated Vaccine Market Competition by Manufacturers

2.1 Global Biological Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Biological Inactivated Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Biological Inactivated Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Biological Inactivated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Biological Inactivated Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Biological Inactivated Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Biological Inactivated Vaccine, Date of Enter into This Industry

2.8 Global Biological Inactivated Vaccine Market Competitive Situation and Trends

2.8.1 Global Biological Inactivated Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Biological Inactivated Vaccine Players Market Share by Revenue

2.8.3 Global Biological Inactivated Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Biological Inactivated Vaccine Market Scenario by Region

3.1 Global Biological Inactivated Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Biological Inactivated Vaccine Sales by Region: 2020-2031

3.2.1 Global Biological Inactivated Vaccine Sales by Region: 2020-2025

3.2.2 Global Biological Inactivated Vaccine Sales by Region: 2026-2031

3.3 Global Biological Inactivated Vaccine Revenue by Region: 2020-2031

3.3.1 Global Biological Inactivated Vaccine Revenue by Region: 2020-2025

3.3.2 Global Biological Inactivated Vaccine Revenue by Region: 2026-2031

3.4 North America Biological Inactivated Vaccine Market Facts & Figures by Country

3.4.1 North America Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Biological Inactivated Vaccine Sales by Country (2020-2031)

3.4.3 North America Biological Inactivated Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Biological Inactivated Vaccine Market Facts & Figures by Country

3.5.1 Europe Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Biological Inactivated Vaccine Sales by Country (2020-2031)

3.5.3 Europe Biological Inactivated Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Biological Inactivated Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Biological Inactivated Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Biological Inactivated Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Biological Inactivated Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Biological Inactivated Vaccine Market Facts & Figures by Country

3.7.1 Latin America Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Biological Inactivated Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Biological Inactivated Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Biological Inactivated Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Biological Inactivated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Biological Inactivated Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Biological Inactivated Vaccine Sales by Type (2020-2031)

4.1.1 Global Biological Inactivated Vaccine Sales by Type (2020-2025)

4.1.2 Global Biological Inactivated Vaccine Sales by Type (2026-2031)

4.1.3 Global Biological Inactivated Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Biological Inactivated Vaccine Revenue by Type (2020-2031)

4.2.1 Global Biological Inactivated Vaccine Revenue by Type (2020-2025)

4.2.2 Global Biological Inactivated Vaccine Revenue by Type (2026-2031)

4.2.3 Global Biological Inactivated Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Biological Inactivated Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Biological Inactivated Vaccine Sales by Application (2020-2031)

5.1.1 Global Biological Inactivated Vaccine Sales by Application (2020-2025)

5.1.2 Global Biological Inactivated Vaccine Sales by Application (2026-2031)

5.1.3 Global Biological Inactivated Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Biological Inactivated Vaccine Revenue by Application (2020-2031)

5.2.1 Global Biological Inactivated Vaccine Revenue by Application (2020-2025)

5.2.2 Global Biological Inactivated Vaccine Revenue by Application (2026-2031)

5.2.3 Global Biological Inactivated Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Biological Inactivated Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Sanofi

6.1.1 Sanofi Company Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Sanofi Biological Inactivated Vaccine Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 GSK

6.2.1 GSK Company Information

6.2.2 GSK Description and Business Overview

6.2.3 GSK Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 GSK Biological Inactivated Vaccine Product Portfolio

6.2.5 GSK Recent Developments/Updates

6.3 Merck

6.3.1 Merck Company Information

6.3.2 Merck Description and Business Overview

6.3.3 Merck Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Merck Biological Inactivated Vaccine Product Portfolio

6.3.5 Merck Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Company Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Pfizer Biological Inactivated Vaccine Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 SII

6.5.1 SII Company Information

6.5.2 SII Description and Business Overview

6.5.3 SII Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 SII Biological Inactivated Vaccine Product Portfolio

6.5.5 SII Recent Developments/Updates

6.6 Valneva

6.6.1 Valneva Company Information

6.6.2 Valneva Description and Business Overview

6.6.3 Valneva Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Valneva Biological Inactivated Vaccine Product Portfolio

6.6.5 Valneva Recent Developments/Updates

6.7 Bharat Biotech

6.7.1 Bharat Biotech Company Information

6.7.2 Bharat Biotech Description and Business Overview

6.7.3 Bharat Biotech Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Bharat Biotech Biological Inactivated Vaccine Product Portfolio

6.7.5 Bharat Biotech Recent Developments/Updates

6.8 KM Biologics

6.8.1 KM Biologics Company Information

6.8.2 KM Biologics Description and Business Overview

6.8.3 KM Biologics Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 KM Biologics Biological Inactivated Vaccine Product Portfolio

6.8.5 KM Biologics Recent Developments/Updates

6.9 Baxter

6.9.1 Baxter Company Information

6.9.2 Baxter Description and Business Overview

6.9.3 Baxter Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Baxter Biological Inactivated Vaccine Product Portfolio

6.9.5 Baxter Recent Developments/Updates

6.10 Bio Farma

6.10.1 Bio Farma Company Information

6.10.2 Bio Farma Description and Business Overview

6.10.3 Bio Farma Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Bio Farma Biological Inactivated Vaccine Product Portfolio

6.10.5 Bio Farma Recent Developments/Updates

6.11 IVAC

6.11.1 IVAC Company Information

6.11.2 IVAC Description and Business Overview

6.11.3 IVAC Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.11.4 IVAC Biological Inactivated Vaccine Product Portfolio

6.11.5 IVAC Recent Developments/Updates

6.12 Takeda

6.12.1 Takeda Company Information

6.12.2 Takeda Description and Business Overview

6.12.3 Takeda Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Takeda Biological Inactivated Vaccine Product Portfolio

6.12.5 Takeda Recent Developments/Updates

6.13 Emergent BioSolutions

6.13.1 Emergent BioSolutions Company Information

6.13.2 Emergent BioSolutions Description and Business Overview

6.13.3 Emergent BioSolutions Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Emergent BioSolutions Biological Inactivated Vaccine Product Portfolio

6.13.5 Emergent BioSolutions Recent Developments/Updates

6.14 Sinergium Biotech

6.14.1 Sinergium Biotech Company Information

6.14.2 Sinergium Biotech Description and Business Overview

6.14.3 Sinergium Biotech Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Sinergium Biotech Biological Inactivated Vaccine Product Portfolio

6.14.5 Sinergium Biotech Recent Developments/Updates

6.15 China Biotechnology

6.15.1 China Biotechnology Company Information

6.15.2 China Biotechnology Description and Business Overview

6.15.3 China Biotechnology Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.15.4 China Biotechnology Biological Inactivated Vaccine Product Portfolio

6.15.5 China Biotechnology Recent Developments/Updates

6.16 Sinovac

6.16.1 Sinovac Company Information

6.16.2 Sinovac Description and Business Overview

6.16.3 Sinovac Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.16.4 Sinovac Biological Inactivated Vaccine Product Portfolio

6.16.5 Sinovac Recent Developments/Updates

6.17 Kangtai Biological

6.17.1 Kangtai Biological Company Information

6.17.2 Kangtai Biological Description and Business Overview

6.17.3 Kangtai Biological Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.17.4 Kangtai Biological Biological Inactivated Vaccine Product Portfolio

6.17.5 Kangtai Biological Recent Developments/Updates

6.18 Zhifei Biological

6.18.1 Zhifei Biological Company Information

6.18.2 Zhifei Biological Description and Business Overview

6.18.3 Zhifei Biological Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.18.4 Zhifei Biological Biological Inactivated Vaccine Product Portfolio

6.18.5 Zhifei Biological Recent Developments/Updates

6.19 AIM Vaccine

6.19.1 AIM Vaccine Company Information

6.19.2 AIM Vaccine Description and Business Overview

6.19.3 AIM Vaccine Biological Inactivated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.19.4 AIM Vaccine Biological Inactivated Vaccine Product Portfolio

6.19.5 AIM Vaccine Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Biological Inactivated Vaccine Industry Chain Analysis

7.2 Biological Inactivated Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Biological Inactivated Vaccine Production Mode & Process Analysis

7.4 Biological Inactivated Vaccine Sales and Marketing

7.4.1 Biological Inactivated Vaccine Sales Channels

7.4.2 Biological Inactivated Vaccine Distributors

7.5 Biological Inactivated Vaccine Customer Analysis

8 Biological Inactivated Vaccine Market Dynamics

8.1 Biological Inactivated Vaccine Industry Trends

8.2 Biological Inactivated Vaccine Market Drivers

8.3 Biological Inactivated Vaccine Market Challenges

8.4 Biological Inactivated Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Emergent Biosolutions

List of Tables

Table 1. Global Biological Inactivated Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Biological Inactivated Vaccine Market Value by Dosage Form, (US$ Million) & (2024 VS 2031)

Table 3. Global Biological Inactivated Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 4. Global Biological Inactivated Vaccine Market Competitive Situation by Manufacturers in 2024

Table 5. Global Biological Inactivated Vaccine Sales (K Units) of Key Manufacturers (2020-2025)

Table 6. Global Biological Inactivated Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 7. Global Biological Inactivated Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 8. Global Biological Inactivated Vaccine Revenue Share by Manufacturers (2020-2025)

Table 9. Global Market Biological Inactivated Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 10. Global Key Players of Biological Inactivated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 11. Global Key Manufacturers of Biological Inactivated Vaccine, Manufacturing Sites & Headquarters

Table 12. Global Key Manufacturers of Biological Inactivated Vaccine, Product Type & Application

Table 13. Global Key Manufacturers of Biological Inactivated Vaccine, Date of Enter into This Industry

Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 15. Global Biological Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Inactivated Vaccine as of 2024)

Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 17. Global Biological Inactivated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 18. Global Biological Inactivated Vaccine Sales by Region (2020-2025) & (K Units)

Table 19. Global Biological Inactivated Vaccine Sales Market Share by Region (2020-2025)

Table 20. Global Biological Inactivated Vaccine Sales by Region (2026-2031) & (K Units)

Table 21. Global Biological Inactivated Vaccine Sales Market Share by Region (2026-2031)

Table 22. Global Biological Inactivated Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 23. Global Biological Inactivated Vaccine Revenue Market Share by Region (2020-2025)

Table 24. Global Biological Inactivated Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 25. Global Biological Inactivated Vaccine Revenue Market Share by Region (2026-2031)

Table 26. North America Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 27. North America Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)

Table 28. North America Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)

Table 29. North America Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 30. North America Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 31. Europe Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 32. Europe Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)

Table 33. Europe Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)

Table 34. Europe Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 35. Europe Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 36. Asia Pacific Biological Inactivated Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 37. Asia Pacific Biological Inactivated Vaccine Sales by Region (2020-2025) & (K Units)

Table 38. Asia Pacific Biological Inactivated Vaccine Sales by Region (2026-2031) & (K Units)

Table 39. Asia Pacific Biological Inactivated Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 40. Asia Pacific Biological Inactivated Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 41. Latin America Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 42. Latin America Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)

Table 43. Latin America Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)

Table 44. Latin America Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 45. Latin America Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 46. Middle East and Africa Biological Inactivated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 47. Middle East and Africa Biological Inactivated Vaccine Sales by Country (2020-2025) & (K Units)

Table 48. Middle East and Africa Biological Inactivated Vaccine Sales by Country (2026-2031) & (K Units)

Table 49. Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 50. Middle East and Africa Biological Inactivated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 51. Global Biological Inactivated Vaccine Sales (K Units) by Type (2020-2025)

Table 52. Global Biological Inactivated Vaccine Sales (K Units) by Type (2026-2031)

Table 53. Global Biological Inactivated Vaccine Sales Market Share by Type (2020-2025)

Table 54. Global Biological Inactivated Vaccine Sales Market Share by Type (2026-2031)

Table 55. Global Biological Inactivated Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 56. Global Biological Inactivated Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 57. Global Biological Inactivated Vaccine Revenue Market Share by Type (2020-2025)

Table 58. Global Biological Inactivated Vaccine Revenue Market Share by Type (2026-2031)

Table 59. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2020-2025)

Table 60. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2026-2031)

Table 61. Global Biological Inactivated Vaccine Sales (K Units) by Application (2020-2025)

Table 62. Global Biological Inactivated Vaccine Sales (K Units) by Application (2026-2031)

Table 63. Global Biological Inactivated Vaccine Sales Market Share by Application (2020-2025)

Table 64. Global Biological Inactivated Vaccine Sales Market Share by Application (2026-2031)

Table 65. Global Biological Inactivated Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 66. Global Biological Inactivated Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 67. Global Biological Inactivated Vaccine Revenue Market Share by Application (2020-2025)

Table 68. Global Biological Inactivated Vaccine Revenue Market Share by Application (2026-2031)

Table 69. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2020-2025)

Table 70. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2026-2031)

Table 71. Sanofi Company Information

Table 72. Sanofi Description and Business Overview

Table 73. Sanofi Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 74. Sanofi Biological Inactivated Vaccine Product

Table 75. Sanofi Recent Developments/Updates

Table 76. GSK Company Information

Table 77. GSK Description and Business Overview

Table 78. GSK Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 79. GSK Biological Inactivated Vaccine Product

Table 80. GSK Recent Developments/Updates

Table 81. Merck Company Information

Table 82. Merck Description and Business Overview

Table 83. Merck Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 84. Merck Biological Inactivated Vaccine Product

Table 85. Merck Recent Developments/Updates

Table 86. Pfizer Company Information

Table 87. Pfizer Description and Business Overview

Table 88. Pfizer Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 89. Pfizer Biological Inactivated Vaccine Product

Table 90. Pfizer Recent Developments/Updates

Table 91. SII Company Information

Table 92. SII Description and Business Overview

Table 93. SII Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 94. SII Biological Inactivated Vaccine Product

Table 95. SII Recent Developments/Updates

Table 96. Valneva Company Information

Table 97. Valneva Description and Business Overview

Table 98. Valneva Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Valneva Biological Inactivated Vaccine Product

Table 100. Valneva Recent Developments/Updates

Table 101. Bharat Biotech Company Information

Table 102. Bharat Biotech Description and Business Overview

Table 103. Bharat Biotech Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Bharat Biotech Biological Inactivated Vaccine Product

Table 105. Bharat Biotech Recent Developments/Updates

Table 106. KM Biologics Company Information

Table 107. KM Biologics Description and Business Overview

Table 108. KM Biologics Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. KM Biologics Biological Inactivated Vaccine Product

Table 110. KM Biologics Recent Developments/Updates

Table 111. Baxter Company Information

Table 112. Baxter Description and Business Overview

Table 113. Baxter Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Baxter Biological Inactivated Vaccine Product

Table 115. Baxter Recent Developments/Updates

Table 116. Bio Farma Company Information

Table 117. Bio Farma Description and Business Overview

Table 118. Bio Farma Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Bio Farma Biological Inactivated Vaccine Product

Table 120. Bio Farma Recent Developments/Updates

Table 121. IVAC Company Information

Table 122. IVAC Description and Business Overview

Table 123. IVAC Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. IVAC Biological Inactivated Vaccine Product

Table 125. IVAC Recent Developments/Updates

Table 126. Takeda Company Information

Table 127. Takeda Description and Business Overview

Table 128. Takeda Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Takeda Biological Inactivated Vaccine Product

Table 130. Takeda Recent Developments/Updates

Table 131. Emergent BioSolutions Company Information

Table 132. Emergent BioSolutions Description and Business Overview

Table 133. Emergent BioSolutions Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Emergent BioSolutions Biological Inactivated Vaccine Product

Table 135. Emergent BioSolutions Recent Developments/Updates

Table 136. Sinergium Biotech Company Information

Table 137. Sinergium Biotech Description and Business Overview

Table 138. Sinergium Biotech Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 139. Sinergium Biotech Biological Inactivated Vaccine Product

Table 140. Sinergium Biotech Recent Developments/Updates

Table 141. China Biotechnology Company Information

Table 142. China Biotechnology Description and Business Overview

Table 143. China Biotechnology Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 144. China Biotechnology Biological Inactivated Vaccine Product

Table 145. China Biotechnology Recent Developments/Updates

Table 146. Sinovac Company Information

Table 147. Sinovac Description and Business Overview

Table 148. Sinovac Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 149. Sinovac Biological Inactivated Vaccine Product

Table 150. Sinovac Recent Developments/Updates

Table 151. Kangtai Biological Company Information

Table 152. Kangtai Biological Description and Business Overview

Table 153. Kangtai Biological Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 154. Kangtai Biological Biological Inactivated Vaccine Product

Table 155. Kangtai Biological Recent Developments/Updates

Table 156. Zhifei Biological Company Information

Table 157. Zhifei Biological Description and Business Overview

Table 158. Zhifei Biological Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 159. Zhifei Biological Biological Inactivated Vaccine Product

Table 160. Zhifei Biological Recent Developments/Updates

Table 161. AIM Vaccine Company Information

Table 162. AIM Vaccine Description and Business Overview

Table 163. AIM Vaccine Biological Inactivated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 164. AIM Vaccine Biological Inactivated Vaccine Product

Table 165. AIM Vaccine Recent Developments/Updates

Table 166. Key Raw Materials Lists

Table 167. Raw Materials Key Suppliers Lists

Table 168. Biological Inactivated Vaccine Distributors List

Table 169. Biological Inactivated Vaccine Customers List

Table 170. Biological Inactivated Vaccine Market Trends

Table 171. Biological Inactivated Vaccine Market Drivers

Table 172. Biological Inactivated Vaccine Market Challenges

Table 173. Biological Inactivated Vaccine Market Restraints

Table 174. Research Programs/Design for This Report

Table 175. Key Data Information from Secondary Sources

Table 176. Key Data Information from Primary Sources

Table 177. Authors List of This Report

List of Figures

Figure 1. Product Picture of Biological Inactivated Vaccine

Figure 2. Global Biological Inactivated Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Biological Inactivated Vaccine Market Share by Type: 2024 & 2031

Figure 4. Inactivated Virus Vaccine Product Picture

Figure 5. Inactivated Bacterial Vaccine Product Picture

Figure 6. Global Biological Inactivated Vaccine Market Value by Dosage Form, (US$ Million) & (2020-2031)

Figure 7. Global Biological Inactivated Vaccine Market Share by Dosage Form: 2024 VS 2031

Figure 8. Liquid Vaccines Product Picture

Figure 9. Freeze-Dried Vaccines Product Picture

Figure 10. Global Biological Inactivated Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Biological Inactivated Vaccine Market Share by Application: 2024 & 2031

Figure 12. Humans

Figure 13. Animals

Figure 14. Global Biological Inactivated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Biological Inactivated Vaccine Market Size (2020-2031) & (US$ Million)

Figure 16. Global Biological Inactivated Vaccine Sales (2020-2031) & (K Units)

Figure 17. Global Biological Inactivated Vaccine Average Price (US$/Unit) & (2020-2031)

Figure 18. Biological Inactivated Vaccine Report Years Considered

Figure 19. Biological Inactivated Vaccine Sales Share by Manufacturers in 2024

Figure 20. Global Biological Inactivated Vaccine Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Biological Inactivated Vaccine Players: Market Share by Revenue in Biological Inactivated Vaccine in 2024

Figure 22. Biological Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Biological Inactivated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)

Figure 25. North America Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)

Figure 26. United States Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)

Figure 29. Europe Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)

Figure 30. Germany Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Biological Inactivated Vaccine Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Biological Inactivated Vaccine Revenue Market Share by Region (2020-2031)

Figure 37. China Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. China Taiwan Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)

Figure 45. Latin America Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Colombia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Biological Inactivated Vaccine Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Biological Inactivated Vaccine Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. UAE Biological Inactivated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Biological Inactivated Vaccine by Type (2020-2031)

Figure 56. Global Revenue Market Share of Biological Inactivated Vaccine by Type (2020-2031)

Figure 57. Global Biological Inactivated Vaccine Price (US$/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Biological Inactivated Vaccine by Application (2020-2031)

Figure 59. Global Revenue Market Share of Biological Inactivated Vaccine by Application (2020-2031)

Figure 60. Global Biological Inactivated Vaccine Price (US$/Unit) by Application (2020-2031)

Figure 61. Biological Inactivated Vaccine Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions